手术切除原发性舌鳞癌中 PD-L1 和 PD-L2 表达的临床病理和预后分析。
Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
机构信息
Department of Clinical Oral Oncology, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Clinical Oral Oncology, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
出版信息
Anticancer Res. 2021 Jan;41(1):101-111. doi: 10.21873/anticanres.14755.
BACKGROUND/AIM: The expression of tumor-associated programmed death-ligand 1 (PD-L1) predicts clinical responses to PD-1-directed immunotherapy. The expression levels of PD-L2, another PD-1 ligand, and its relationship with responses to PD-1-targeting therapy in oral squamous cell carcinoma (OSCC) remain unclear. Furthermore, the clinicopathological characteristics and prognostic effects of the expression of PD-L1 and PD-L2 in OSCC have not yet been elucidated.
MATERIALS AND METHODS
The expression of PD-L1 and PD-L2 was immunohistochemically examined in 98 tongue carcinomas. Furthermore, the expression levels of PD-L1 and PD-L2 in OSCC cell lines and their relationships with those of MMP2 and MMP9 were assessed.
RESULTS
The expression levels of PD-L1 and PD-L2 correlated with those of MMP2 and MMP9. The expression of PD-L1 and/or PD-L2 was detected in OSCC cells, and their levels correlated with those of MMP9. The prognosis of patients with PD-L1- and PD-L2-positive tumors was significantly worse.
CONCLUSION
PD-L1 and PD-L2 status is potentially a novel predictor of the prognosis of OSCC and provides a rationale for the development of novel immunotherapies.
背景/目的：肿瘤相关程序性死亡配体 1（PD-L1）的表达预测了对 PD-1 靶向免疫治疗的临床反应。另一种 PD-1 配体 PD-L2 的表达水平及其与口腔鳞状细胞癌（OSCC）对 PD-1 靶向治疗的反应之间的关系尚不清楚。此外，PD-L1 和 PD-L2 在 OSCC 中的表达的临床病理特征和预后影响尚未阐明。
材料和方法
对 98 例舌癌进行了 PD-L1 和 PD-L2 的免疫组织化学检查。此外，还评估了 OSCC 细胞系中 PD-L1 和 PD-L2 的表达水平及其与 MMP2 和 MMP9 的关系。
结果
PD-L1 和 PD-L2 的表达水平与 MMP2 和 MMP9 的表达水平相关。PD-L1 和/或 PD-L2 在 OSCC 细胞中表达，其水平与 MMP9 相关。PD-L1 和 PD-L2 阳性肿瘤患者的预后明显较差。
结论
PD-L1 和 PD-L2 的状态可能是 OSCC 预后的一个新的预测因子，并为新的免疫治疗的发展提供了依据。
Zotero 插件